Please assess the completion status of the following clinical trial:

Trial Title: Study of Efficacy and Safety of Vildagliptin as add-on Insulin Therapy in T2DM Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of T2DM by standard criteria.~* HbA1c ≥ 7.0 to ≤ 10% at Visit 1.~* Age: ≥ 20 to \< 75 years old at Visit 1.~* BMI ≥ 20 to ≤ 35 kg/m2 at Visit 1.~Exclusion Criteria:~* FPG ≥ 270 mg/dL (≥15 mmol/L) at Visit 1.~* Type 1 diabetes, monogenic diabetes, diabetes resulting from pancreatic injury, or secondary forms of diabetes.~* Significant heart diseases~* Hepatic disorder~Other protocol defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- Vildagliptin (LAF237) (Type: EXPERIMENTAL): Patients received vildagliptin (LAF237) 50 mg tablets twice daily for 12 weeks. Patients continued on a stable dose of long-acting or intermediate-acting or pre-mixed insulin, and metformin if applicable, throughout the study
- Placebo (Type: PLACEBO_COMPARATOR): In this arm, patients received vildagliptin 50 mg matching placebo tablets twice daily for 12 weeks. Patients continued on a stable dose of long-acting or intermediate-acting or pre-mixed insulin, and metformin if applicable, throughout the study

Based on this trial design, predict the completion outcome and termination type (if applicable).